|
|
|
¼öÇ÷ÀÇÇÐ (5ÆÇ) 2023Àü¸é °³Á¤ÆÇ |
|
|
|
|
¡Ø±³È¯ ¹× ¹ÝÇ°¾È³» :
- ±³È¯À̳ª ¹ÝÇ°½Ã »óÇ° ¼ö·ÉÈÄ 3ÀÏÀ̳» ±³È¯À̳ª ¹ÝÇ° Àǻ縦 ¾Ë·ÁÁֽðí ÀÏÁÖÀÏÀ̳»¿¡ ÀúÈñÂÊÀ¸·Î »óÇ°ÀÌ ÀÔ°íµÇ¾î¾ßÇÕ´Ï´Ù. ½ÃÀÏÀÌ °æ°úµÇ¸é ¹ÝÇ°ÀÌ ºÒ°¡ÇÕ´Ï´Ù. - º¯½É¿¡ ÀÇÇÑ ±³È¯À̳ª ¹ÝÇ°½Ã, ¹è¼Ûºñ´Â °í°´´Ô²²¼ ºÎ´ãÇϽøç, ¿À¹è¼ÛÀ̳ª »óÇ° ºÒ·®½Ã¿¡´Â ¹«·á ±³È¯ÀÌ °¡´ÉÇÕ´Ï´Ù. - ¹ÝÇ°½Ã¿¡´Â ¹ÝÇ°»óÇ° °Ë¼öÈÄ Ä«µå Ãë¼Ò¸¦ Çص帮°Å³ª ÅëÀå,Àû¸³±ÝµîÀ¸·Î ȯºÒ Á¶Ä¡ ÇØ µå¸³´Ï´Ù. |
|
¡Ø¹è¼Û¾È³» :
- Á¦ÁÖµµ¹× µµ¼»ê°£Áö¿ªÀº Åùèºñ°¡ Ãß°¡µÉ¼ö ÀÖ½À´Ï´Ù. |
|
|
|
|
|
|
|
|
|
Á¦5ÆÇ ¸Ó¸®¸»
¡°¼öÇ÷ÀÇÇÐ Á¦5ÆÇ(Àü¸é°³Á¤ÆÇ)¡±Àº ´ëÇѼöÇ÷ÇÐȸ ÁÖ°üÀ¸·Î´Â ÃÖÃÊ·Î ¹ß°£µÇ´Â ¼öÇ÷ÀÇÇÐ ±³°ú¼ÀÌ°í, ¿ÃÇØ 2023³âÀº ¡°¼öÇ÷ÀÇÇС± ÃÊÆÇÀÌ ¹ß°£µÈ Áö 30³âÀÌ µÇ´Â ÇØ¿©¼ ±× Àǹ̰¡ ´õ¿í Å©´Ù°í ÇÒ ¼ö
ÀÖ½À´Ï´Ù.
¡°¼öÇ÷ÀÇÇÐ Á¦5ÆÇ(Àü¸é°³Á¤ÆÇ)¡±¿¡´Â ¹ßÀüÇÏ°í ÀÖ´Â ±¹³»¿Ü ÃֽŠ¼öÇ÷ÀÇÇÐ ÇмúÀÚ·á ¹× °ü·Ã Á¦µµµéÀÇ º¯È »çÇ×À» ¹Ý¿µÇÏ¿´À¸¸ç, ÃÑ 12°³ÀÇ ÀåÀ¸·Î ÀÌ·ç¾îÁ® ÀÖ½À´Ï´Ù. ÀÌÀü ¡°¼öÇ÷ÀÇÇС± ¸ñÂ÷ ¼ø¼¸¦
º¯°æÇÏ¿© ¼öÇ÷ÀÇÇÐÀÇ ÀÓ»óÀû È°¿ë ºÎºÐÀÎ ¼öÇ÷ÀÇ ¿øÄ¢, ¼öÇ÷ÀÌ»ó¹ÝÀÀ, ȯÀÚÇ÷¾×°ü¸®, ¼öÇ÷ÀûÁ¤¼º°ü¸®, Ä¡·áÀû ¼ººÐäÁý¼ú µîÀÇ ³»¿ëÀ» Àü¹ÝºÎ¿¡ ¹èÄ¡ÇÏ°í, ¼öÇ÷ÀÇÇÐÀÇ ±âº» Áö½ÄÀÎ ÇåÇ÷ ¹× Ç÷¾×ÀÇ º¸Á¸, Ç÷¾×Á¦Á¦, Ç÷¾×Çü, ¼öÇ÷Àü°Ë»ç µîÀÇ ³»¿ëÀº ÈĹݺο¡ ¹èÄ¡ÇÏ¿© ¼öÇ÷ÀÇÇÐÀÇ ÀÓ»óÀû Á߿伺°ú È°¿ëµµ¸¦ °Á¶ÇÏ°íÀÚ ÇÏ¿´½À´Ï´Ù.
¼öÇ÷ÀÇ ±âº»¿øÄ¢°ú ÇÔ²² ¿©·¯°¡Áö ÀÓ»ó »óȲ¿¡¼ÀÇ ¼öÇ÷¿ä¹ý¿¡ ´ëÇÑ ±â¼ú ¹× Èñ±ÍÇ÷¾×Çü ȯÀÚÀÇ ¼öÇ÷À» »õ·Ó°Ô Ãß°¡ÇÏ¿´À¸¸ç, ¼öÇ÷°¡À̵å¶óÀο¡ ¼Ò°³µÇ¾î ÀÖ´Â ¼öÇ÷ÀÌ»ó¹ÝÀÀÀÇ Á¾·ù ¹× Á¤ÀÇ¿Í ¹ß»ý±âÀü, °ü¸®¿¡ ´ëÇØ ÀÚ¼¼È÷ ±â¼úÇÏ¿© ¾ÈÀüÇÑ ¼öÇ÷¿¡ µµ¿òÀÌ µÇµµ·Ï ÇÏ¿´½À´Ï´Ù. ¶ÇÇÑ ¿äÁò ¼öÇ÷°ú ÇÔ²² °¢±¤ ¹Þ°í Àִ ȯÀÚÇ÷¾×°ü¸® ºÐ¾ß¸¦ óÀ½À¸·Î ¡°¼öÇ÷ÀÇÇС±¿¡ ÇÑ ÆÄÆ®·Î µµÀÔÇÏ¿´À¸¸ç, 2020³âºÎÅÍ ±¹³»¿¡¼ ½ÃÇà µÇ°í ÀÖ´Â ¼öÇ÷ÀûÁ¤¼º Æò°¡¿¡ ¹ß¸ÂÃß¾î ¼öÇ÷ÀûÁ¤¼º Æò°¡ °ü·Ã ³»¿ë ¹× ¼öÇ÷°¡À̵å¶óÀÎ, ¼öÇ÷°ü¸®À§¿øȸ ¹× ¼öÇ÷°ü¸®½ÇÀÇ ¿î¿µ µîÀÇ º¯ÈÇÏ°í ÀÖ´Â ¼öÇ÷ÀÇÇÐºÐ¾ß ±¹³» Á¦µµÀÇ Áß¿ä ³»¿ëµéÀ» ´ã¾Ò½À´Ï´Ù. ÇöÀç »ç¿ëµÇ°í ÀÖ´Â Ä¡·áÀû ¼ººÐäÁý¼ú¿¡ ´ëÇÑ ±âº» ¿ø¸® ¹× °¢ ¼ú±â¿Í ÇÔ²², ±¹³» ÷´ÜÀç»ýÀÇ·á°¡ ÁÖ¸ñÀ» ¹Þ°í ÀÖ´Â Çö ½ÃÁ¡¿¡¼ ¼öÇ÷ÀÇÇÐ ºÐ¾ß¿¡ Áß¿äÇÑ ¹Ì·¡ µ¿·ÂÀ¸·Î ÀÚ¸® ¸Å±èÇÒ ¼¼Æ÷Ä¡·á¿¡ ´ëÇÑ ³»¿ëµµ Á¦5ÆÇ¿¡ »õ·Ó°Ô Æ÷ÇÔÇÏ¿´½À´Ï´Ù. ±×¿Ü ÇåÇ÷ ¹× Ç÷¾×º¸Á¸, Ç÷¾×Á¦Á¦¿¡ µû¸¥ ¼öÇ÷¿ä¹ý, Ç÷¾×Çü, ¼öÇ÷Àü °Ë»ç µî ¼öÇ÷ÀÇÇÐÀÇ ÇÙ½ÉÀÌ µÇ´Â ±âº» Áö½Ä¿¡ ´ëÇØ ÃֽŠ¾÷µ¥ÀÌÆ® µÈ ³»¿ëµéÀ» ±â¼úÇÏ¿´À¸¸ç, ±âÁ¸ÀÇ ¼öÇ÷°Ë»ç ÁöħÀ» ´ëÆø ¼öÁ¤ÇÏ¿© ÇöÀç Áß¿äÇÏ°Ô »ç¿ëµÇ´Â ¼ú±â¸¦ ÀÚ¼¼ÇÏ°Ô ¼³¸íÇÏ¿© ½ÇÁ¦ °Ë»ç½Ç¿¡¼ À¯¿ëÇÏ°Ô »ç¿ëÇÒ ¼ö ÀÖµµ·Ï ÇÏ¿´½À´Ï´Ù. ¸¶Áö¸·À¸·Î ¼öÇ÷ÀÇ ½ÇÁ¦»ó
Ȳ¿¡ µµ¿òÀÌ µÇ´Â 10°³ Áõ·Ê¸¦ ´ã¾Æ ÇöÀå¿¡¼ À¯»çÇÑ Áõ·Ê¸¦ °æÇèÇÒ ½Ã¿¡ È°¿ëÇÒ ¼ö ÀÖµµ·Ï ±¸¼ºÇÏ¿´½À´Ï´Ù.
¡°¼öÇ÷ÀÇÇÐ Á¦5ÆÇ(Àü¸é°³Á¤ÆÇ)¡±À¸·Î »õ·Ó°Ô ź»ýÇÑ ¼öÇ÷ÀÇÇÐ ±³°ú¼¿¡ µ¶ÀںеéÀÇ ¸¹Àº °ü½É ºÎŹµå¸®¸ç, ³¡À¸·Î ÈçÄèÈ÷ ÈÄÇÐÀ» À§ÇØ ¡°¼öÇ÷ÀÇÇС±¿¡ ´ã±ä ¸ðµç °ÍÀ» Àü¼öÇØ ÁֽŠÇѱԼ· ±³¼ö´Ô°ú ´ëÇѼöÇ÷
ÇÐȸÀÇ ¿ª»ç¸¦ ÇÔ²² ÀÌ·ç¾î ³»½Å ¸ðµç ¼±¹è ±³¼ö´Ôµé²² ´Ù½Ã Çѹø Áø½ÉÀ¸·Î °¨»ç¿Í Á¸°æÀ» ÀüÇÕ´Ï´Ù.
2023³â 5¿ù
°øµ¿ÆíÂùÀ§¿øÀå
´ëÇѼöÇ÷ÇÐȸ ÆíÁýÀÌ»ç ÀÓÁöÇâ
±âȹÀÌ»ç ¹Ú°æ¿î
|
|
|
|
|
|
01. ¼öÇ÷ÀÇ ½ÇÁ¦(Transfusion Practice) / 1
1. ¼öÇ÷ÀÇ ±âº»¿øÄ¢(Basic Principles of Transfusion) -- 1
2. ÀÀ±Þ¼öÇ÷/´ë·®¼öÇ÷(Emergency Transfusion/Massive Transfusion) -- 7
3. À̽Ŀ¡¼ÀÇ ¼öÇ÷(Transfusion in Transplantation) -- 15
4. ÀÚ°¡¼öÇ÷(Autologous Transfusion) -- 26
5. ºñ¿¹±âÇ×ü º¸À¯ÀÚÀÇ ¼öÇ÷(Transfusion for Patients with Unexpected Antibodies) -- 31
6. ¸é¿ª¿ëÇ÷ºóÇ÷¿¡¼ÀÇ ¼öÇ÷¿ä¹ý(Transfusion in Immune Hemolytic Anemia) -- 33
7. ½Å»ý¾Æ¿¡¼ÀÇ ¼öÇ÷(Transfusion in Infants) -- 40
8. ¼Ò¾Æ¼öÇ÷¿ä¹ý(Pediatric Transfusion Practices) -- 46
9. Èñ±ÍÇ÷¾×Çü ȯÀÚÀÇ ¼öÇ÷(Transfusion for Patients with Rare Blood Groups) -- 49
02. ¼öÇ÷ÀÌ»ó¹ÝÀÀ(Adverse Transfusion Reaction) / 61
1. ¼·Ð(Introduction) -- 61
2. ±Þ¼º¿ëÇ÷¼öÇ÷¹ÝÀÀ(Acute Hemolytic Transfusion Reaction, AHTR) -- 63
3. Áö¿¬¼º¿ëÇ÷¼öÇ÷¹ÝÀÀ(Delayed Hemolytic Transfusion Reaction, DHTR) -- 69
4. Áö¿¬¼ºÇ÷ûÇÐÀû¼öÇ÷¹ÝÀÀ(Delayed Serologic Transfusion Reaction, DSTR) -- 72
5. ¹ß¿¼ººñ¿ëÇ÷¼öÇ÷¹ÝÀÀ(Febrile Non-Hemolytic Transfusion Reaction, FNHTR) -- 73
6. ¾Ë·¹¸£±â¹ÝÀÀ(Allergic Reaction)/¾Æ³ªÇʶô½Ã½º¹ÝÀÀ(Anaphylactic Reaction) -- 74
7. ÀúÇ÷¾Ð¹ÝÀÀ(Hypotensive Transfusion Reaction) -- 76
8. ¼öÇ÷°ü·Ã±Þ¼ºÆó¼Õ»ó(Transfusion-related Acute Lung Injury, TRALI) -- 79
9. ¼öÇ÷°ü·Ã¼øȯ·®°ú´Ù(Transfusion-associated Circulatory Overload, TACO) -- 82
10. ¼öÇ÷°ü·ÃÈ£Èí°ï¶õ(Transfusion-associated Dyspnea, TAD) -- 83
11. ¼öÇ÷ÈÄÀÚ¹ÝÁõ(Post Transfusion Purpura, PTP) -- 83
12. ¼öÇ÷°ü·ÃÀ̽ÄÆí´ë¼÷ÁÖº´(Transfusion-associated Graft-versus-Host Disease, TA-GVHD) -- 84
13. ¼öÇ÷ÀüÆļº°¨¿°(Transfusion Transmitted Infection, TTI) -- 85
14. Ç÷¾×¾ÈÀü°¨½Ãü°è(Hemovigilance) -- 100
03. ȯÀÚÇ÷¾×°ü¸®(Patient Blood Management, PBM) / 113
1. ȯÀÚÇ÷¾×°ü¸®(Patient Blood Management) -- 113
2. ȯÀÚÇ÷¾×°ü¸® Àü·« µµÀÔ°ú Àû¿ë(Introduction and Implementation of PBM strategy) -- 119
04. ¼öÇ÷ÀûÁ¤¼º°ü¸®(Management of Transfusion Appropriateness) / 137
1. ¼öÇ÷°¡À̵å¶óÀΰú ¼öÇ÷ÀûÁ¤¼º Æò°¡(Transfusion Guideline and Audit) -- 137
2. ¼öÇ÷°ü¸®À§¿øȸ ¹× ¼öÇ÷°ü¸®½ÇÀÇ ¿î¿µ(Transfusion Management Committee and
Operation of Transfusion Management Department) -- 141
05. Ä¡·áÀû ¼ººÐäÁý¼ú(Therapeutic Apheresis) / 147
1. ±âº»¿ø¸®(General Principles) -- 147
2. Ä¡·áÀû ¼ººÐäÁý¼ú ½Ã ȯÀÚ°ü¸®(Management of the Therapeutic Apheresis Patients) -- 149
3. Ç÷À屳ȯ¼ú(Plasma Exchange) -- 156
4. ¼¼Æ÷¼ººÐäÁý¼ú(Apheresis of Cell Components) -- 167
06. ¼¼Æ÷Ä¡·á(Cellular Therapy) / 179
1. ¼¼Æ÷Ä¡·áÁ¦ »ý»êÀ» À§ÇÑ GMP (Good Manufacturing Practice) ½Ã¼³(GMP Facility for
Production of Cellular Therapy Products) -- 179
2. Àç»ýÀÇÇÐ(Regenerative Medicine), Áٱ⼼Æ÷(Stem Cell), ¼¼Æ÷¸é¿ªÄ¡·á(Cellular Immunotherapy) -- 181
3. CAR T¼¼Æ÷ ¹× NK¼¼Æ÷(CAR T Cells and NK Cells) -- 182
07. ÇåÇ÷ ¹× Ç÷¾×ÀÇ º¸Á¸(Blood Donation and Preservation of Blood) / 191
1. ÇåÇ÷(Blood Donation) -- 191
2. ÇåÇ÷Ç÷¾× ¼±º°°Ë»ç(Screening tests for donated blood) -- 206
3. Ç÷¾×ÀÇ º¸Á¸(Preservation of Blood) -- 210
08. Ç÷¾×Á¦Á¦ ¹× ¼öÇ÷¿ä¹ý(Blood Component Therapy) / 219
1. ¼ººÐ¼öÇ÷¿ä¹ý(Blood Component Therapy) -- 219
2. ÀüÇ÷(Whole Blood) -- 219
3. ³óÃàÀûÇ÷±¸(Red Blood Cells, RBCs) -- 221
4. Ç÷¼ÒÆÇÁ¦Á¦(Platelets) -- 223
5. ½Å¼±µ¿°áÇ÷Àå(Fresh Frozen Plasma, FFP) -- 229
6. µ¿°áħÀüÁ¦Á¦(Cryoprecipitates) -- 232
7. Ç÷¾×Á¦Á¦ÀÇ ¹éÇ÷±¸Á¦°Å(Leukocyte Reduction of Blood Components) -- 234
8. Ç÷¾×Á¦Á¦ÀÇ ¼¼Ã´(Washed Blood Components) -- 236
9. Ç÷¾×Á¦Á¦ÀÇ ¹æ»ç¼±Á¶»ç(Irradiation of Blood Components) -- 237
10. Ç÷¾×Á¦Á¦ÀÇ º´¿øü ºÒÈ°È(Pathogen Inactivation of Blood Components) -- 239
11. Ç÷ÀåºÐȹÁ¦Á¦(Plasma Derivatives) -- 241
12. ±¹¿Ü¿¡¼ »ç¿ë ÁßÀ̰ųª ¿¬±¸ ÁßÀÎ Ç÷¾×Á¦Á¦(Blood Products Being Used or Researched Abroad) -- 248
09. Ç÷¾×Çü(Blood Group Systems) / 257
1. ¼öÇ÷ÀÇÇп¡¼ ¸é¿ªÇÐ ¹× À¯ÀüÇÐ(Immunology and Blood Group Genetics in Transfusion Medicine) -- 257
2. ABO Ç÷¾×Çü(ABO Blood Group) -- 269
3. Rh Ç÷¾×Çü(Rh Blood Group) -- 283
4. ±âŸ Ç÷¾×Çü(Other Blood Groups) -- 291
5. °ú¸³±¸¿Í Ç÷¼ÒÆÇÀÇ Ç׿ø ¹× Ç×ü(Antigens and Antibodies of Granulocytes and Platelets) -- 311
6. HLA Ç׿ø ¹× Ç×ü(Human Leukocyte Antigens and Antibodies) -- 325
10. ¼öÇ÷Àü°Ë»ç(Pretransfusion Tests) / 351
1. äÇ÷ ¹× °Ëü(Blood Collection and Specimen) -- 351
2. ÀûÇ÷±¸ Ç׿ø-Ç×ü ¹ÝÀÀ(Red Blood Cell Antigen-Antibody Reactions) -- 353
3. Çױ۷κҸ°°Ë»ç(Antihuman Globulin Test, AHG Test ȤÀº Coombs¡¯ Test) -- 356
4. Ç÷¾×Çü°Ë»ç(Blood Typing) -- 359
5. ºñ¿¹±âÇ×ü ¼±º°°Ë»ç(Unexpected Antibody Screening) -- 360
6. ºñ¿¹±âÇ×ü µ¿Á¤°Ë»ç(Unexpected Antibody Identification) -- 363
7. ±³Â÷½ÃÇè(Crossmatch) -- 365
8. ¼öÇ÷Àü°Ë»çÀÇ ÀÚµ¿È(Automated Pretransfusion Testing) -- 370
11. ¼öÇ÷°Ë»ç Áöħ(Laboratory Procedures) / 375
1. Ç÷¾×Çü°Ë»ç(Blood Typing) -- 375
2. Ç×ü ¼±º°, µ¿Á¤ ¹× ±³Â÷½ÃÇè °Ë»ç(Antibody Screening, Identification, and Crossmatch Testing) -- 388
3. Á÷Á¢Çױ۷κҸ°°Ë»ç ¾ç¼º ½Ã ½ÃÇàÇÒ ¼ö ÀÖ´Â °Ë»ç
(Investigation of Positive DAT Result) -- 409
12. Áõ·Ê(Cases) / 423
ã¾Æº¸±â(Index) / 435 |
|
|
|
|
|
|
|
|
µî·ÏµÈ ¼ÆòÀÌ ¾ø½À´Ï´Ù. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|